Pharmaceutical Preparations
Standard Industrial Classification: SIC 2834
Industry Insider Sentiment Analysis
The Pharmaceutical Preparations sector (SIC 2834) acts as a critical barometer for broader economic health. Our real-time monitoring reveals total transactions. Monitoring "cluster buying" is one of the most reliable leading indicators for future sector performance. By analyzing aggregate data across this specific Standard Industrial Classification, investors can filter out individual company volatility and identify high-conviction trends. When multiple directors and officers within the same industry move capital simultaneously, it often signals an upcoming sector-wide revaluation or a fundamental shift in supply chain dynamics that has yet to be recognized by the broader public market.
| Filing Date | Trade Date | Ticker | Company | Reporting Person | Relationship | Type | Price | Qty | Total, $ | Owned After |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025-09-15 19:31 | 2025-09-12 | CALC | CalciMedica, Inc. | Roberts Eric W | Director, Officer, 10% owner | BUY | $3.12 | 5,000 | $15,600 | 78,250 |
| 2025-09-15 23:26 | 2025-09-12 | MRSN | Mersana Therapeutics, Inc. | Huber Martin H. Jr. | Director, Officer | OPT+S | $7.31 | 2,012 | $14,708 | 9,572 |
| 2025-09-15 23:07 | 2025-09-12 | ZVRA | ZEVRA THERAPEUTICS, INC. | Shih Alvin | Director | BUY | $7.89 | 20,000 | $157,800 | 20,000 |
| 2025-09-16 00:39 | 2025-09-12 | SUPN | SUPERNUS PHARMACEUTICALS, INC. | Mottola Frank | Officer | OPT+S | $45.87 | 5,000 | $229,350 | 15,496 |
| 2025-09-15 23:05 | 2025-09-12 | RAPP | Rapport Therapeutics, Inc. | PAUL STEVEN M | Director | BUY | $24.65 | 41,666 | $1,027,113 | 41,666 |
| 2025-09-15 19:45 | 2025-09-12 | GALT | GALECTIN THERAPEUTICS INC | CALLICUTT JACK W | Officer | OPT+S | $6.44 | 8,706 | $56,054 | 7,614 |
| 2025-09-15 19:45 | 2025-09-12 | GALT | GALECTIN THERAPEUTICS INC | LEWIS JOEL | Director, Officer | OPT+S | $6.36 | 14,000 | $89,048 | 832,592 |
| 2025-09-15 23:23 | 2025-09-12 | INSM | INSMED Inc | Schaeffer Orlov S Nicole | Officer | OPT+S | $145.45 | 76,520 | $11,129,926 | 36,461 |
| 2025-09-15 23:22 | 2025-09-12 | INSM | INSMED Inc | SHAROKY MELVIN MD | Director | SELL | $145.39 | 10,000 | $1,453,900 | 262,675 |
| 2025-09-16 00:00 | 2025-09-11 | PTCT | PTC THERAPEUTICS, INC. | Boulding Mark Elliott | Officer | OPT+S | $61.18 | 47,249 | $2,890,585 | 103,901 |
| 2025-09-15 23:47 | 2025-09-15 | CYTK | CYTOKINETICS INC | Blum Robert I | Director, Officer | SELL | $49.77 | 5,000 | $248,850 | 373,108 |
| 2025-09-16 02:16 | 2025-09-12 | ANIP | Ani Pharmaceuticals Inc. | Cook Meredith | Officer | SELL | $98.42 | 400 | $39,368 | 76,074 |
| 2025-09-12 23:30 | 2025-09-10 | NUVL | Nuvalent, Inc. | Pelish Henry E. | Officer | OPT+S | $78.83 | 3,725 | $293,642 | 65,963 |
| 2025-09-13 01:00 | 2025-09-11 | VTRS | Viatris Inc | Le Goff Corinne | Officer | SELL | $10.25 | 7,032 | $72,045 | 35,299 |
| 2025-09-13 03:28 | 2025-09-10 | AARD | Aardvark Therapeutics, Inc. | Lee Tien-Li | Director, Officer, 10% owner | BUY | $8.03 | 20,000 | $160,654 | 1,533,384 |
| 2025-09-13 03:39 | 2025-09-11 | AKRO | Akero Therapeutics, Inc. | Young Jonathan | Officer | SELL | $43.02 | 586 | $25,210 | 196,898 |
| 2025-09-13 03:39 | 2025-09-11 | AKRO | Akero Therapeutics, Inc. | Yale Catriona | Officer | SELL | $43.02 | 659 | $28,350 | 90,829 |
| 2025-09-13 03:38 | 2025-09-11 | AKRO | Akero Therapeutics, Inc. | White William Richard | Officer | SELL | $43.02 | 659 | $28,350 | 57,752 |
| 2025-09-13 03:36 | 2025-09-11 | AKRO | Akero Therapeutics, Inc. | Rolph Timothy | Officer | SELL | $43.02 | 553 | $23,790 | 166,571 |
| 2025-09-13 03:36 | 2025-09-10 | AKRO | Akero Therapeutics, Inc. | Cheng Andrew | Director, Officer | OPT+S | $43.23 | 31,796 | $1,374,665 | 473,902 |
| 2025-09-12 23:32 | 2025-09-10 | ZLAB | Zai Lab Ltd | Smiley Joshua L | Officer | BUY | $28.91 | 10,000 | $289,100 | 86,604 |
| 2025-09-12 23:38 | 2025-09-10 | ONC | BeOne Medicines Ltd. | Lee Chan Henry | Officer | OPT+S | $325.53 | 10,006 | $3,257,289 | 0 |
| 2025-09-12 23:07 | 2025-09-11 | RNA | Avidity Biosciences, Inc. | Flanagan W. Michael | Officer | OPT+S | $38.94 | 20,000 | $778,702 | 80,195 |
| 2025-09-12 23:11 | 2025-09-12 | RARE | Ultragenyx Pharmaceutical Inc. | Parschauer Karah Herdman | Officer | SELL | $31.17 | 2,450 | $76,367 | 73,271 |
| 2025-09-12 23:01 | 2025-09-10 | APLS | Apellis Pharmaceuticals Inc. | Watson David O. | Officer | SELL | $26.17 | 20,000 | $523,400 | 50,136 |
| 2025-09-13 04:45 | 2025-09-12 | CRMD | CorMedix Inc. | Todisco Joseph | Officer | OPT+S | $13.00 | 50,000 | $650,000 | 509,496 |
| 2025-09-13 03:00 | 2025-09-11 | MIRM | Mirum Pharmaceuticals, Inc. | Brege Laura | Director | OPT+S | $74.40 | 17,000 | $1,264,868 | 15,703 |
| 2025-09-13 00:09 | 2025-09-11 | XERS | Xeris Biopharma Holdings, Inc. | PERSKY MARLA | Director | SELL | $7.72 | 15,500 | $119,610 | 142,000 |
| 2025-09-13 03:00 | 2025-09-12 | MIRM | Mirum Pharmaceuticals, Inc. | BJERKHOLT ERIC | Officer | OPT+S | $76.01 | 9,578 | $728,024 | 39,945 |
| 2025-09-13 00:30 | 2025-09-11 | CYRX | Cryoport, Inc. | Hariri Robert J | Director | OPT+S | $9.71 | 25,000 | $242,738 | 51,275 |
| 2025-09-12 15:36 | 2025-08-01 | CPIX | CUMBERLAND PHARMACEUTICALS INC | Young Caroline | Director | BUY | $3.29 | 121 | $398 | 32,942 |
| 2025-09-12 15:35 | 2025-08-01 | CPIX | CUMBERLAND PHARMACEUTICALS INC | Jones James | Director | BUY | $3.29 | 262 | $862 | 43,938 |
| 2025-09-12 15:32 | 2025-08-01 | CPIX | CUMBERLAND PHARMACEUTICALS INC | Krogulski Kenneth | Director | BUY | $3.29 | 1,372 | $4,516 | 289,717 |
| 2025-09-12 15:34 | 2025-08-01 | CPIX | CUMBERLAND PHARMACEUTICALS INC | KAZIMI A J | Director, Officer, 10% owner | BUY | $3.29 | 262 | $862 | 5,700,030 |
| 2025-09-13 00:09 | 2025-09-10 | PMVP | PMV Pharmaceuticals, Inc. | ORBIMED ADVISORS LLC | 10% owner | SELL | $1.80 | 500,000 | $900,000 | 5,975,291 |
| 2025-09-12 23:42 | 2025-09-11 | TGTX | TG THERAPEUTICS, INC. | Lonial Sagar | Director | SELL | $32.24 | 20,852 | $672,268 | 94,061 |
| 2025-09-12 01:13 | 2025-09-11 | RAPP | Rapport Therapeutics, Inc. | Young Wendy B. | Director | BUY | $22.60 | 3,500 | $79,100 | 9,500 |
| 2025-09-12 00:50 | 2025-09-09 | CNTA | Centessa Pharmaceuticals plc | Bush Tia L | Officer | OPT+S | $21.00 | 49,792 | $1,045,841 | 121,503 |
| 2025-09-12 00:47 | 2025-09-09 | CNTA | Centessa Pharmaceuticals plc | HUSSAIN IQBAL J | Officer | OPT+S | $21.00 | 40,000 | $840,104 | 105,386 |
| 2025-09-12 00:45 | 2025-09-09 | CNTA | Centessa Pharmaceuticals plc | Accardi Mario Alberto | Officer | OPT+S | $20.00 | 7,000 | $140,000 | 205,566 |
| 2025-09-12 00:05 | 2025-09-09 | IONS | IONIS PHARMACEUTICALS INC | Baroldi Joseph | Officer | OPT+S | $62.16 | 11,950 | $742,838 | 31,926 |
| 2025-09-11 23:24 | 2025-09-11 | CAMP | Camp4 Therapeutics Corp | Gold Kelly | Officer | BUY | $1.65 | 6,060 | $9,999 | 67,877 |
| 2025-09-11 23:23 | 2025-09-11 | CAMP | Camp4 Therapeutics Corp | Mandel-Brehm Josh | Director, Officer | BUY | $1.65 | 6,060 | $9,999 | 278,417 |
| 2025-09-11 23:25 | 2025-09-11 | CAMP | Camp4 Therapeutics Corp | Maricich Yuri | Officer | BUY | $1.65 | 6,060 | $9,999 | 6,060 |
| 2025-09-12 00:20 | 2025-09-09 | DNTH | Dianthus Therapeutics, Inc. /DE/ | Savitz Ryan | Officer | OPT+S | $35.00 | 20,000 | $700,000 | 0 |
| 2025-09-12 00:10 | 2025-09-09 | ONC | BeOne Medicines Ltd. | Wang Lai | Officer | SELL | $350.06 | 5,000 | $1,750,312 | 0 |
| 2025-09-11 23:48 | 2025-09-11 | CAMP | Camp4 Therapeutics Corp | Nashat Amir | Director, 10% owner | BUY | $1.53 | 1,307,189 | $1,999,999 | 197,661 |
| 2025-09-12 00:04 | 2025-09-09 | IONS | IONIS PHARMACEUTICALS INC | O'NEIL PATRICK R. | Officer | OPT+S | $64.56 | 21,000 | $1,355,661 | 57,130 |
| 2025-09-11 19:00 | 2025-09-09 | CALC | CalciMedica, Inc. | Roberts Eric W | Director, Officer, 10% owner | BUY | $3.15 | 2,343 | $7,378 | 73,250 |
| 2025-09-12 02:36 | 2025-09-10 | SMMT | Summit Therapeutics Inc. | Zanganeh Mahkam | Director, Officer, 10% owner | BUY | $17.69 | 338,394 | $5,984,769 | 556,093,090 |
Sector-Wide Insider Alpha
Analyzing insider movements across the Pharmaceutical Preparations sector provides a macro-view of executive conviction. When multiple leaders in different companies within the same SIC code (2834) simultaneously buy shares, it often indicates an industry-wide undervaluation or a positive shift in market cycles.
SEC Filings in Pharmaceutical Preparations
Every transaction in the Pharmaceutical Preparations industry is reported via Form 4 disclosures. By filtering these filings by industry, investors can detect institutional-scale sentiment shifts before they are reflected in broader market indices, following the capital flow of those with intimate industry knowledge.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.